Human IgG1 are purified from human plasma by fractionation, ion exchange and affinity chromatography. The purified IgG represent a single subclass and light chain type (κ). Source material has been shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests. Negative control in experiments with recombinant proteins fused to human IgG1 Fc.
Product Details
| Host: | Human |
| |
| Isotype: | IgG1 |
| |
| Source: | Purified from human plasma. |
| |
| Species reactivity: | Species independent
|
| |
| Applications: | ELISA, Flow Cytometry, IP, WB
|
| |
| Application Notes: | Negative control in assays where receptors:Fc (IgG1) are used. |
| |
| Purity Detail: | Purified from myeloma plasma. |
| |
| Endotoxin Content: | <0.1EU/µg antibody (LAL test; BioWhittaker) |
| |
| Formulation: | Lyophilized from PBS, pH 7.2. |
| |
| Reconstitution: | Reconstitute with 100µl sterile water. |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored as recommended. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | +4°C |
| |
| Technical Info/Product Notes: | Cited samples:
For an overview on cited samples please click here. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity: A. Nagase-Zembutsu, et al.; Cancer Sci.
107, 674 (2016),
Application(s): Flow cytometry,
Abstract;
Full Text
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment: J. Hasegawa, et al.; Cancer Biol. Ther.
17, 1158 (2016),
Abstract;
Full Text
Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells: Y. Imai, et al.; J. Immunol.
195, 421 (2015),
Abstract;
Full Text
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression: S.P. Santoro, et al.; Cancer Immunol. Res.
3, 68 (2015),
Abstract;
Full Text
Specific Notch receptor–ligand interactions control human TCR-αβ/γδ development by inducing differential Notch signal strength: I. van de Walle, et al.; J. Exp. Med.
210, 683 (2013),
Application(s): Binding studies using human K562 cells,
Abstract;
Full Text
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells: C. Ming Lim, et al.; Oncoimmunology
2, e24677 (2013),
Application(s): 51Cr release assay using human peripheral blood monocytes (PBMCs),
Abstract;
Full Text
Fc gamma receptor CD64 modulates the inhibitory activity of infliximab: K.A. Wojtal, et al.; PLoS One
7, e43361 (2012),
Application(s): FC receptor blocking of human fibroblasts and THP-1 cells,
Abstract;
Full Text
Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC: J. Luka, et al.; J. Biomed. Biotechnol.
2011, 934757 (2011),
Abstract;
Full Text
A subset of myeloid dendritic cells derived from peripheral blood monocytes represented a predominant subset characterized by their potential tumor-inhibiting activity: M. Wang, et al.; In Vitro Cell Dev. Biol. Anim.
45, 398 (2009),
Abstract;
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain: L. Wu, et al.; J. Virol.
83, 5077 (2009),
Abstract;
Full Text
Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts: E.L. Rosenthal, et al.; Mol. Cancer Ther.
6, 1230 (2007),
Abstract;
Full Text
Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity: G. Cantarella, et al.; Cell Death Differ.
10, 134 (2003),
Abstract;
Full Text
